Abiraterone Acetate (Zytiga®)

 
Common name: Abiraterone Acetate
Brand name: Zytiga®


What is Abiraterone Acetate?

Abiraterone Acetate is a drug used to treat advanced prostate cancer (metastatic castrate resistant prostate cancer). Abiraterone acetate blocks the production of testosterone to stop the spread and growth of prostate cancer cells.

Abiraterone Acetate is used in combination with a corticosteroid (such as prednisone) and has been approved for the following uses:
  • It is given to men who previously received docetaxel chemotherapy after failure of androgen deprivation therapy.
  • It is also given to men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.


How is Abiraterone Acetate administered?

Abiraterone Acetate is administered orally as a tablet.


What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received abiraterone acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Diarrhea
  • Frequent urination
  • High blood pressure
  • Hot flashes
  • Joint pain
  • Low potassium (hypokalemia)
  • Muscle aches
  • Upset stomach

Is Abiraterone Acetate covered in my province or territory?*

Abiraterone acetate is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
Abiraterone acetate is not covered by provincial/territorial drug programs in:
  • Manitoba
  • Prince Edward Island
  • Nunavut
  • Northwest Territories
  • Yukon
The pan-Canadian Oncology Drug Review (pCODR) recommends funding abiraterone acetate (zytiga®).
To read pCODRs full recommendation, please click here.

For more information on pCODR, please visit www.pcodr.ca

Zytiga Access Program

Patient Assistance Programs are offered by pharmaceutical companies to provide medications and/or financial assistance to those who cannot afford to pay for their medicine.

Please call 1-855-998-4423 for more information and to see if you qualify for this program.

​*Source: http://drugcover​age.ca/en-ca/search-results.aspx?ID=16783
 


Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More


Click here for news archive